Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10
July 29, 2022 17:46 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
June 30, 2022 07:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
June 23, 2022 07:30 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital
June 07, 2022 08:05 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 07:30 ET
|
Evaxion Biotech
Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a clinical trial for EVX-02 with all patients...
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02
May 10, 2022 07:30 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11
April 29, 2022 12:16 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies
April 06, 2022 07:30 ET
|
Evaxion Biotech
Tuesday, April 12th @ 12:30 pm ET COPENHAGEN, Denmark, April 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company...
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 22, 2022 06:30 ET
|
Evaxion Biotech
Completed follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) raising net proceeds of $24.9 million after deducting underwriting discounts,...
Evaxion Biotech Strengthens Management Team with Two Senior Appointments
March 14, 2022 07:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, March 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) is a clinical-stage biotechnological company specializing in the development of AI-powered immunotherapies...